Alimemazine
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
- Alimemazine
- Pharmacist Assessment Report
- Alimemazine: H1-receptor antagonist (phenothiazine antihistamine) → IgE responsiveness, atopic
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Alimemazine: H1-receptor antagonist (phenothiazine antihistamine) → IgE responsiveness, atopic
One-Sentence Summary
Alimemazine is a phenothiazine-class antihistamine. The TxGNN model predicts it may be relevant for IgE responsiveness, atopic, but there are currently no clinical trials and no publications supporting this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | IgE responsiveness, atopic |
| TxGNN Prediction Score | 0.9960 |
| Evidence Level | L5 |
| Canada Market Status | Not marketed (licenses canceled: 2 of 2) |
| Number of DINs | 2 (marketed: 0) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Alimemazine belongs to the phenothiazine antihistamine class, which blocks H1 receptors and has anticholinergic and sedative effects.
Atopic IgE responsiveness is a predisposition or phenotype rather than a discrete treatable disease. H1 blockade may relieve downstream symptoms such as rhinitis, itching and hives, but it does not change IgE production or sensitization. The link is a model prediction based on proximity to allergic conditions. No clinical evidence was found, and there is no defined clinical endpoint for this entity.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 01926306 | PANECTYL | Not recorded | Not recorded |
| 01926292 | PANECTYL | Not recorded | Not recorded |
Safety Considerations
- Contraindication-related conditions (not from label text): The compiled data flag possible concerns in conditions including long QT syndrome, torsades de pointes, orthostatic hypotension, epilepsy, liver disease, neutropenia, agranulocytosis, leukopenia, thrombocytopenia, benign prostatic hyperplasia, hyperglycemia, and myocardial infarction. These should be checked against the official label.
- Drug Interactions: 100 interactions were found. The two rated Major are bupropion and potassium citrate. Examples of Moderate interactions include epinephrine, morphine, atropine, hyoscyamine, glycopyrronium, loperamide, clarithromycin, famotidine, and several antidiabetic drugs (acarbose, alogliptin, canagliflozin, chlorpropamide, dapagliflozin, albiglutide).
Please refer to the package insert for warnings and full contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but no trials or publications address this condition, and it is a predisposition rather than a treatable disease with a defined clinical endpoint. Evidence is at the model-prediction level only (L5).
To proceed, the following is needed:
- A clearly defined clinical condition and endpoint related to atopic IgE responsiveness
- Clinical or preclinical studies directly examining alimemazine in this setting
- Package insert warnings and contraindications from Health Canada for the safety review
- Mechanism of action data
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.